This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.